BLOG / 🇺🇸 United States / regulatory compliance · · daily

US SEC Trading Suspension Halt Orders — August 28, 2026

USA Trading Suspensions

By Gunpowder Editorial ·

12 high priority 12 total filings analysed

Executive Summary

This digest covers 12 filings related to US trading suspensions, delistings, and regulatory halts, all concentrated on August 24-28, 2026.

A dominant theme is the wave of Nasdaq non-compliance notices, with 10 of 12 filings involving Nasdaq-listed companies facing issues ranging from late filings (Netcapital, Gulf Resources, Shuttle Pharmaceuticals, AiRWA) to bid price deficiencies (KALA BIO, GeoVax, Jupiter Neurosciences, BioAtla) and equity shortfalls (My Size, Socket Mobile). Notably, BioAtla received a final delisting affirmation from Nasdaq's Listing Council, with trading suspended effective August 31, 2026, marking the most severe outcome. The filings reveal a pattern of companies exhausting compliance extensions and reverse stock splits, only to face accelerated delisting procedures. Insider activity data was sparse across filings, but the absence of insider buying in the face of these notices is a bearish signal. The aggregate trend shows a tightening regulatory environment, with Nasdaq increasingly denying second chances to companies that have already used reverse splits or failed to meet alternative listing standards. The only non-Nasdaq filing, Oragenics on NYSE American, underscores that exchange compliance pressures are broad-based. Overall, the stream signals heightened delisting risk for micro-cap and pre-revenue biotech/pharma companies, with potential for significant price dislocations and forced selling.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from August 19, 2026.

Investment Signals (12)

  • BioAtla (BCAB) (BEARISH)
    ▲

    Final delisting affirmed by Nasdaq Listing Council on Aug 26, trading suspended Aug 31. Shares expected to move to OTC Markets, likely causing severe liquidity and price decline. No insider buying reported in the filing, indicating management may have given up on Nasdaq listing.

  • KALA BIO (KALA) (BEARISH)
    ▲

    Received bid price delisting notice after 1-for-50 reverse split on May 11 failed to maintain compliance. Ineligible for 180-day grace period. Company plans to appeal, but historical success rate for such appeals is low. No insider purchases disclosed.

  • GeoVax Labs (GOVX) (BEARISH)
    ▲

    Dual non-compliance—bid price below $1.00 and stockholders' equity below $2.5M. Already used a 1-for-25 reverse split in Jan 2026. Hearing deadline Sep 3; suspension possible Sep 8. No insider buying.

  • Jupiter Neurosciences (JUNS) (MIXED)
    ▲

    Delisting notice for market value below $35M, but regained bid price compliance as of Aug 26. This partial win may give the company a stronger appeal argument. However, market value deficiency remains unresolved.

  • Netcapital (NCPL) (BEARISH)
    ▲

    Late 10-K filing triggers 60-day compliance plan window. Stock and warrants trade normally for now. No insider activity reported; watch for plan submission by Oct 23.

  • Gulf Resources (GURE) (BEARISH)
    ▲

    Still delinquent on both Q1 and Q2 2026 10-Qs despite prior extension to Aug 31 for Q1. Filed 2025 10-K on Aug 17, showing some progress, but ongoing delinquency is a red flag. No insider buying.

  • My Size (MYSZ) (MIXED)
    ▲

    Equity deficiency of $153K below $2.5M threshold. Has 45 days to submit plan. Small shortfall may be easier to remedy via capital raise or equity infusion. No insider activity.

  • Socket Mobile (SCKT) (BEARISH)
    ▲

    Failed equity test ($2.38M vs $2.5M) and also failed alternative market value and net income tests. This triple failure makes compliance harder. No insider buying.

  • Oragenics (OGEN) (MIXED)
    ▲

    NYSE American non-compliance for equity ($3.7M vs $4M threshold) and net losses. Has until Feb 2028 to regain compliance—longest runway among all filings. Stock gets '.BC' designation.

  • AiRWA (AIRW) (BEARISH)
    ▲

    Delisting notice for late 10-K due to acquisition consolidation delays. Has until Jan 25, 2027 to comply if plan accepted. The acquisition-driven delay could be resolved, but uncertainty remains. No insider activity.

  • Shuttle Pharmaceuticals (SHPH) (BEARISH)
    ▲

    Late 10-Q filing triggers 60-day plan deadline. No immediate trading impact. No insider buying.

  • Envirotech Vehicles (EVTV) (BULLISH)
    ▲

    Remediated shareholder approval deficiency by removing four executives. Nasdaq closed the matter. This is a positive resolution, but the company must still meet other listing requirements. No insider buying.

Risk Flags (10)

  • BioAtla/Imminent Delisting↓ [HIGH RISK]
    ▼

    Final delisting affirmed; trading suspended Aug 31. Shares moving to OTC will likely see significant price decline and reduced liquidity. No insider buying suggests management sees limited upside.

  • KALA BIO/Accelerated Delisting↓ [HIGH RISK]
    ▼

    Ineligible for standard 180-day compliance period after reverse split. Appeal is the only option, but success is uncertain. No insider buying.

  • GeoVax Labs/Dual Deficiency↓ [HIGH RISK]
    ▼

    Both bid price and equity non-compliance. Already used reverse split. Hearing deadline Sep 3; suspension possible Sep 8. No insider buying.

  • Jupiter Neurosciences/Market Value Deficiency↓ [HIGH RISK]
    ▼

    Despite regaining bid price compliance, market value remains below $35M. Delisting notice already received. Appeal pending.

  • Gulf Resources/Chronic Late Filings↓ [HIGH RISK]
    ▼

    Still delinquent on Q1 and Q2 2026 10-Qs. Prior extension for Q1 expires Aug 31. Failure to file could trigger immediate delisting.

  • Socket Mobile/Triple Failure↓ [HIGH RISK]
    ▼

    Failed equity, market value, and net income tests. Limited pathways to compliance. No insider buying.

  • My Size/Equity Shortfall↓ [MEDIUM RISK]
    ▼

    Only $153K below threshold, but no insider buying or capital raise announced. Small shortfall could be remedied, but no action yet.

  • Netcapital/Late Filing↓ [MEDIUM RISK]
    ▼

    60-day plan window. If plan rejected, appeal needed. No insider buying.

  • Shuttle Pharmaceuticals/Late Filing↓ [MEDIUM RISK]
    ▼

    60-day plan window. No insider buying.

  • AiRWA/Acquisition Integration Risk↓ [MEDIUM RISK]
    ▼

    Late 10-K due to acquisition consolidation. If integration issues persist, compliance may be delayed further.

Opportunities (8)

  • Envirotech Vehicles/Remediation Success↓ (OPPORTUNITY)
    ◆

    Quickly resolved shareholder approval deficiency by removing four executives. Nasdaq closed the matter. This shows proactive management and could restore investor confidence.

  • Oragenics/Long Compliance Runway↓ (OPPORTUNITY)
    ◆

    Has until Feb 2028 to regain compliance—longest among all filings. Stock trades with '.BC' designation but remains listed. Time to execute turnaround.

  • Jupiter Neurosciences/Bid Price Compliance↓ (OPPORTUNITY)
    ◆

    Regained $1.00 bid price compliance as of Aug 26. This strengthens their appeal against the market value delisting. If market value improves, delisting risk could be avoided.

  • My Size/Small Equity Shortfall↓ (OPPORTUNITY)
    ◆

    Only $153K below $2.5M threshold. A small capital raise or asset sale could quickly remedy the deficiency. Watch for compliance plan by Oct 9.

  • Netcapital/60-Day Window↓ (OPPORTUNITY)
    ◆

    Has until Oct 23 to submit compliance plan. If plan is accepted, extension to Feb 2027 possible. Stock and warrants continue trading normally.

  • Shuttle Pharmaceuticals/60-Day Window↓ (OPPORTUNITY)
    ◆

    Has until Oct 27 to submit compliance plan. If accepted, extension to Feb 2027 possible. No immediate trading impact.

  • AiRWA/Acquisition-Driven Delay↓ (OPPORTUNITY)
    ◆

    Late filing due to acquisition consolidation, not operational issues. If integration completes successfully, compliance could be regained by Jan 2027.

  • Gulf Resources/Progress on 10-K↓ (OPPORTUNITY)
    ◆

    Filed delinquent 2025 10-K on Aug 17, showing some improvement. If Q1 and Q2 10-Qs are filed soon, delisting risk could be averted.

Sector Themes (6)

  • Nasdaq Delisting Wave
    ◆

    10 of 12 filings involve Nasdaq-listed companies facing delisting or suspension. This cluster suggests a broader regulatory tightening, possibly due to increased scrutiny from Nasdaq's Listing Qualifications Department. Companies that have used reverse splits are being denied second chances, accelerating the path to delisting.

  • Reverse Split Trap
    ◆

    KALA BIO and GeoVax both used reverse stock splits (1-for-50 and 1-for-25, respectively) to regain bid price compliance, but then failed to maintain it. Nasdaq's policy of denying these companies a standard 180-day compliance period creates a 'trap' where reverse splits are a temporary fix but lead to faster delisting if they fail.

  • Micro-Cap Distress
    ◆

    All 12 companies are micro-caps with market capitalizations likely below $100M. The filings reveal a pattern of chronic non-compliance, late filings, and equity shortfalls, indicating systemic financial distress in this segment. Investors should be wary of micro-cap biotech and tech stocks with weak balance sheets.

  • Late Filing Epidemic
    ◆

    4 of 12 filings (Netcapital, Gulf Resources, Shuttle Pharmaceuticals, AiRWA) are for late periodic reports (10-K or 10-Q). This suggests a broader issue with internal controls and accounting resources among small-cap companies. Late filings often precede more serious compliance issues.

  • Appeal as Last Resort
    ◆

    Multiple companies (KALA BIO, GeoVax, Jupiter Neurosciences, BioAtla) are appealing delisting decisions to Nasdaq Hearings Panels or the Listing Council. The low success rate of these appeals (especially for companies with multiple deficiencies) suggests that appeals are often a delaying tactic rather than a viable path to continued listing.

  • OTC Migration Risk
    ◆

    BioAtla's expected move to OTC Markets highlights the risk for delisted stocks: reduced liquidity, lower valuations, and potential loss of institutional coverage. This could create a negative feedback loop for other companies facing similar outcomes.

Watch List (8)

  • BioAtla↓
    👁

    Trading suspension expected Aug 31. Watch for OTC Markets quotation and any strategic process updates (initiated Mar 2026). Potential for significant price decline. [Aug 31, 2026]

  • GeoVax Labs↓
    👁

    Hearing request deadline Sep 3. If not filed, suspension Sep 8. Watch for appeal outcome and any equity infusion to address $2.5M requirement. [Sep 3, 2026]

  • KALA BIO↓ (TBD)
    👁

    Appeal hearing date to be set. Watch for any news on bid price recovery or capital raise.

  • Jupiter Neurosciences↓ (TBD)
    👁

    Appeal hearing date to be set. Watch for market value improvement or strategic alternatives.

  • Netcapital↓
    👁

    Compliance plan due Oct 23. Watch for plan submission and Nasdaq acceptance. [Oct 23, 2026]

  • My Size↓
    👁

    Compliance plan due Oct 9. Watch for capital raise or equity infusion to address $153K shortfall. [Oct 9, 2026]

  • Gulf Resources↓
    👁

    Q1 2026 10-Q extension expires Aug 31. Watch for filing of both Q1 and Q2 10-Qs. [Aug 31, 2026]

  • Oragenics↓
    👁

    Compliance plan due Sep 25. Watch for plan details and any equity improvement. [Sep 25, 2026]

Filing Analyses (12)
Netcapital Inc. 8-K negative materiality 8/10

28-08-2026

Netcapital Inc. received a Nasdaq delinquency notice on August 24, 2026, for failing to file its Annual Report (Form 10-K) for the fiscal year ended April 30, 2026, violating Listing Rule 5250(c)(1). The company has 60 days (until October 23, 2026) to submit a compliance plan, with a possible extension to February 9, 2027. While the notice has no immediate effect on trading, non-compliance will be publicly broadcast, and there is no assurance Nasdaq will accept the plan or that compliance can be regained.

  • · The delinquency notification was received on August 24, 2026, and the 8-K was filed on August 28, 2026.
  • · The company's common stock (NCPL) and warrants (NCPLW) are listed on Nasdaq.
  • · If the compliance plan is not accepted, the company can appeal to a Nasdaq Hearings Panel under Rule 5815(a).
  • · A press release announcing the notice was issued on August 28, 2026, and is attached as Exhibit 99.1.
KALA BIO, Inc. 8-K negative materiality 9/10

28-08-2026

KALA BIO, Inc. received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its common stock has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days (July 16, 2026 through August 26, 2026). Because the company had already effected a 1-for-50 reverse stock split on May 11, 2026, Nasdaq has determined that KALA is not eligible for the standard 180-day compliance period. The company intends to appeal the determination by requesting a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the Panel's decision, though there is no assurance of a favorable outcome.

  • · The company's common stock trades under the symbol KALA on The Nasdaq Capital Market.
  • · The non-compliance period ran from July 16, 2026 through August 26, 2026.
  • · The company had previously effected a 1-for-50 reverse stock split on May 11, 2026, which disqualified it from the standard 180-day compliance period.
  • · A timely request for a hearing will stay any suspension or delisting action pending the Panel's decision.
JUPITER NEUROSCIENCES, INC. 8-K negative materiality 9/10

28-08-2026

Jupiter Neurosciences received a delisting notice from Nasdaq on August 27, 2026, because its market value of listed securities remained below the $35 million minimum for over 30 consecutive trading days and it failed to regain compliance by the August 25, 2026 deadline. The company intends to appeal the determination and request a hearing before the Nasdaq Hearings Panel, which would stay further action pending a final decision. However, the company did regain compliance with the $1.00 minimum bid price requirement as of August 26, 2026, though it cannot assure it will maintain that compliance.

  • · The delisting notice was received on August 27, 2026, and the compliance deadline was August 25, 2026.
  • · The company had previously been notified on February 26, 2026, of the market value deficiency.
  • · The company regained compliance with the minimum bid price rule ($1.00 per share) for the 10 consecutive business days ending August 26, 2026.
  • · There is no assurance that the appeal will be successful or that the company will maintain bid price compliance.
GeoVax Labs, Inc. 8-K negative materiality 9/10

28-08-2026

GeoVax Labs, Inc. received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its common stock will be delisted due to non-compliance with the minimum $1.00 bid price requirement. The closing bid price remained below $1.00 for 30 consecutive business days from July 16, 2026 through August 26, 2026, and the company is ineligible for a customary compliance period because it effected a 1-for-25 reverse stock split on January 12, 2026. GeoVax also faces a separate deficiency regarding the minimum $2,500,000 stockholders' equity requirement. The company plans to request a hearing before the Nasdaq Hearings Panel by September 3, 2026, which will stay any suspension; however, there is no assurance that continued listing will be granted.

  • · Trading suspension expected at the opening of business on September 8, 2026 if no timely hearing request is made.
  • · Deadline to request a hearing is September 3, 2026.
  • · Company also faces non-compliance with the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b).
Envirotech Vehicles, Inc. 8-K mixed materiality 8/10

28-08-2026

Envirotech Vehicles, Inc. (now Azio AI Holdings) received a Nasdaq deficiency notice on August 28, 2026, for failing to obtain shareholder approval before completing a change-of-control merger on July 2, 2026, which triggered the appointment of five Azio AI-affiliated executives. However, the company remediated the issue by removing four of those executives (Simon Yu, David Shiue, Gary Chen, Jenny Yang) effective August 27, 2026, and Nasdaq has closed the matter. Chris Young remains CEO, and the delisting notice has no immediate effect on listing, though the company must still comply with other continued listing requirements.

  • · The deficiency was under Nasdaq Listing Rule 5635(b) regarding shareholder approval for change-of-control issuances.
  • · The merger closed on July 2, 2026, and the deficiency was remediated by August 27, 2026.
  • · Simon Yu remains employed by the company but is no longer an executive officer or Section 16 officer.
  • · The company's common stock trades under the symbol AZIO on the Nasdaq Capital Market.
My Size, Inc. 8-K negative materiality 9/10

28-08-2026

My Size, Inc. received a Nasdaq deficiency letter on August 25, 2026, for failing to meet the minimum stockholders' equity requirement of $2,500,000, reporting only $2,347,000 as of June 30, 2026. The company has 45 days (until October 9, 2026) to submit a compliance plan and may receive up to 180 additional days to regain compliance. There is no immediate impact on listing, but failure to regain compliance could lead to delisting.

  • · The deficiency letter was received on August 25, 2026, and the 8-K was filed on August 28, 2026.
  • · The company has until October 9, 2026, to submit a compliance plan.
  • · If the compliance plan is accepted, Nasdaq may grant an extension through February 21, 2027.
  • · If the compliance plan is not accepted or compliance is not regained, the Staff would issue a delisting determination, and the company could request a hearing to stay delisting.
Shuttle Pharmaceuticals Holdings, Inc. 8-K negative materiality 8/10

28-08-2026

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) received a Nasdaq notice on August 28, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days (until October 27, 2026) to submit a compliance plan, and if accepted, Nasdaq may grant an exception until February 22, 2027. While the notice does not immediately affect trading, failure to regain compliance could lead to delisting, and there is no assurance the plan will be accepted.

  • · The company's common stock trades under the symbol SHPH on Nasdaq.
  • · If Nasdaq does not accept the compliance plan, the company may appeal to a hearings panel.
  • · Nasdaq will broadcast a noncompliance indicator over its market data network.
  • · The company is working diligently to complete and file the Form 10-Q as soon as practicable.
GULF RESOURCES, INC. 8-K negative materiality 9/10

28-08-2026

Gulf Resources, Inc. (GURE) received a Nasdaq notice on August 24, 2026, for failing to timely file its Q2 2026 Form 10-Q, violating Listing Rule 5250(c)(1). The company had previously been granted an extension until August 31, 2026, to file its delinquent Q1 2026 Form 10-Q, but as of this report, both the Q1 and Q2 2026 Form 10-Qs remain unfiled. While the notice has no immediate effect on listing, the company must submit an updated compliance plan by August 28, 2026, and the ongoing delinquency poses a continued risk to its Nasdaq listing.

  • · The company filed its delinquent 2025 Form 10-K on August 17, 2026, and is no longer delinquent on that filing.
  • · Amendments to the 2024 Form 10-K were filed on July 27, 2026, and August 24, 2026.
  • · The company remains delinquent in filing both the Q1 2026 Form 10-Q and the Q2 2026 Form 10-Q as of the press release date.
  • · The company's common stock trades on the Nasdaq Capital Market under the symbol GURE.
SOCKET MOBILE, INC. 8-K negative materiality 9/10

28-08-2026

Socket Mobile, Inc. received a Nasdaq deficiency notice on August 24, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting equity of only $2,382,624 as of June 30, 2026. The company also does not meet alternative listing standards based on market value of listed securities ($35 million minimum) or net income from continuing operations ($500,000 minimum). While the notice has no immediate effect on trading, Socket Mobile must submit a compliance plan by October 8, 2026, and faces potential delisting if it cannot regain compliance within a possible 180-day extension.

  • · The company also failed alternative listing standards under Rule 5550(b)(2) (market value of listed securities at least $35 million) and Rule 5550(b)(3) (net income from continuing operations at least $500,000 in the most recent fiscal year or two of the last three).
  • · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
  • · The notice has no immediate effect on trading; shares continue to trade on Nasdaq under symbol SCKT.
ORAGENICS INC 8-K negative materiality 9/10

28-08-2026

Oragenics Inc. received a notice from NYSE American on August 26, 2026, for non-compliance with continued listing standards due to stockholders' equity of $3.7M at June 30, 2026 (below the $4M/$6M thresholds) and net losses in its last five fiscal years. The company must submit a compliance plan by September 25, 2026, and has until February 25, 2028 to regain compliance; if unsuccessful, it faces potential delisting, which could reduce liquidity, market price, and access to capital.

  • · Equity shortfall: $3.7M vs. $4M (Section 1003(a)(ii)) and $6M (Section 1003(a)(iii)).
  • · Common stock will trade with '.BC' designation (below compliance) but remains listed during the review period.
  • · Plan deadline: September 25, 2026; compliance deadline: February 25, 2028.
  • · Net losses reported in last five fiscal years ended December 31, 2025.
AIRWA INC. 8-K negative materiality 9/10

28-08-2026

AiRWA Inc. received a delisting notice from Nasdaq on August 24, 2026, for failing to file its Annual Report on Form 10-K for the period ended April 30, 2026, due to delays in consolidating financial results from a significant acquisition. The company has 60 days to submit a compliance plan and potentially up to 180 days from the filing due date to regain compliance, but there is no assurance of success. The company issued a press release on August 28, 2026, disclosing the notice.

  • · The delisting notice was triggered by failure to file the Annual Report on Form 10-K for the period ended April 30, 2026.
  • · The delay was attributed to the time-consuming consolidation of financial results from a significant acquisition.
  • · If Nasdaq accepts the compliance plan, the company has until January 25, 2027, to regain compliance.
  • · The company expects to file the Form 10-K before the October 23, 2026, deadline for plan submission.
  • · There is no assurance that the company will be able to satisfy Nasdaq's continued listing requirements.
BioAtla, Inc. 8-K negative materiality 10/10

28-08-2026

BioAtla, Inc. (BCAB) received a final delisting determination from Nasdaq's Listing Council on August 26, 2026, affirming the earlier Panel decision to delist its common stock due to non-compliance with the $1.00 bid price requirement and failure to demonstrate compliance with the $2.5 million stockholders' equity requirement. Trading on Nasdaq is expected to be suspended at the opening of business on August 31, 2026, unless the Nasdaq Board calls the matter for review. The company expects its shares to be eligible for quotation on the OTC Markets system under the same symbol BCAB, but warns this may materially adversely affect trading price and volume. The company's ongoing strategic process to explore options to maximize shareholder value, initiated in March 2026, continues with no assurance of any resulting agreements or transactions.

  • · The company had previously received a delisting determination on February 6, 2026, and had requested a review by the Listing Council, which stayed the suspension pending its review.
  • · The Listing Council's decision to affirm the delisting was issued on August 26, 2026.
  • · Unless the Nasdaq Board calls the matter for review, trading will be suspended at the opening of business on August 31, 2026, and a Form 25-NSE will be filed with the SEC.
  • · The company expects its common stock to be immediately eligible for quotation on OTC Markets under the symbol BCAB, but there is no assurance a market will develop or be maintained.
  • · The company's strategic process to explore options to maximize shareholder value, initiated in March 2026, is ongoing with no assurance of any resulting agreements or transactions.

Get daily alerts with 12 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 12 filings

Start free trial Browse all digests

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US SEC Trading Suspension Halt Orders

August 18, 2026

US SEC Trading Suspension Halt Orders — August 18, 2026

August 14, 2026

US SEC Trading Suspension Halt Orders — August 14, 2026

August 12, 2026

US SEC Trading Suspension Halt Orders — August 12, 2026

August 11, 2026

US SEC Trading Suspension Halt Orders — August 11, 2026

🇺🇸 More from United States

View all →

August 21, 2026

US Merger & Acquisition SEC Filings — August 21, 2026

US Merger & Acquisition SEC Filings

August 21, 2026

USA Insider Trading Pulse — August 21, 2026

USA Insider Trading Pulse

August 21, 2026

USA Corporate Actions — August 21, 2026

USA Corporate Actions

August 21, 2026

US Corporate Board Director Changes SEC Filings — August 21, 2026

US Corporate Board Director Changes SEC Filings
← All United States digests